Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Beijing China (2001)

Organization Overview

First Clinical Trial
2013
NCT01999231
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronavirus Infections (Phase 2)

Dysentery (Phase 1)

Dysentery, Bacillary (Phase 1)

Gastroenteritis (Phase 2)

Meningitis (Phase 2)

Meningitis, Meningococcal (Phase 2)

Meningococcal Infections (Phase 2)

Pneumonia (Phase 3)

Pneumonia, Pneumococcal (Phase 3)

Tuberculosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 33
  • # of Trial APIs: 20